Tanioka, M., Fan, C., Parker, J. S., Hoadley, K. A., Hu, Z., Li, Y., . . . Perou, C. M. (2018). Integrated analysis of RNA and DNA from the phase III trial CALGB 40601 identifies predictors of response to trastuzumab-based neoadjuvant chemotherapy in HER2-positive breast cancer. Clin Cancer Res.
Chicago-стиль цитированияTanioka, Maki, et al. "Integrated Analysis of RNA and DNA From the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-based Neoadjuvant Chemotherapy in HER2-positive Breast Cancer." Clin Cancer Res 2018.
MLA-цитированиеTanioka, Maki, et al. "Integrated Analysis of RNA and DNA From the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-based Neoadjuvant Chemotherapy in HER2-positive Breast Cancer." Clin Cancer Res 2018.